Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia

Atherosclerosis. 2015 Sep;242(1):226-9. doi: 10.1016/j.atherosclerosis.2015.07.024. Epub 2015 Jul 14.

Abstract

Background: Lipoprotein (a), also called Lp(a), is a cardiovascular disease (CVD) risk factor. Statins do not lower Lp(a), this may at least partly explain residual CVD risk in statin-treated patients with familial hypercholesterolemia (FH). We investigated the association of Lp(a) levels with atherosclerosis in these patients.

Methods and results: We performed ultrasonography in 191 statin-treated FH patients (50% men; 48 ± 15 years) to detect carotid plaques and determine carotid intima-media thickness (C-IMT). Patients with high versus low Lp(a) levels (≤0.3 g/L) had similar plaque prevalence (36 and 31%, p = 0.4) and C-IMT (0.59 ± 0.12 and 0.59 ± 0.13 mm, p = 0.8). Patients with and without plaques had similar Lp(a) levels (median 0.35 (IQR: 0.57) and 0.24 (0.64) g/L, respectively, p = 0.4).

Conclusions: The Lp(a) levels were not associated with atherosclerosis in the carotid arteries of statin-treated FH patients. This suggests that adequate statin treatment delays carotid atherosclerosis in FH independently of Lp(a) levels.

Keywords: Carotid intima media thickness; Carotid plaque presence; Familial hypercholesterolemia; Lipoprotein (a); Residual risk.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Biomarkers / blood
  • Carotid Arteries / diagnostic imaging*
  • Carotid Artery Diseases / diagnostic imaging
  • Carotid Artery Diseases / epidemiology
  • Carotid Artery Diseases / prevention & control*
  • Carotid Intima-Media Thickness*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hyperlipoproteinemia Type II / blood
  • Hyperlipoproteinemia Type II / diagnosis
  • Hyperlipoproteinemia Type II / drug therapy*
  • Hyperlipoproteinemia Type II / epidemiology
  • Lipoprotein(a) / blood*
  • Male
  • Middle Aged
  • Netherlands
  • Plaque, Atherosclerotic*
  • Predictive Value of Tests
  • Prevalence
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoprotein(a)